Do Traders Think Synaptogenix Inc (SNPX) Can Keep Climbing Thursday?

Synaptogenix Inc (SNPX) stock has risen 34.92% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Synaptogenix Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SNPX!

See Full SNPX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With SNPX Stock Today?

Synaptogenix Inc (SNPX) stock is trading at $6.80 as of 2:20 PM on Thursday, Jul 28, a rise of $0.29, or 4.45% from the previous closing price of $6.51. The stock has traded between $6.55 and $7.37 so far today. Volume today is more active than usual. So far 187,476 shares have traded compared to average volume of 55,514 shares.

More About Synaptogenix Inc

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing. Click Here to get the full Stock Report for Synaptogenix Inc stock.